A study of SAR444245 combined with cemiplimab for the treatment of participants with various advanced skin cancers (Pegathor Skin 201)

Trial Identifier: ACT16845
Sponsor: Sanofi
Start Date: July 2021
Primary Completion Date: August 2023
Study Completion Date: February 2025
Condition: Skin Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
AUSTRALIA, New South Wales Macquarie University, New South Wales, AUSTRALIA, 2109
CHILE Temuco, CHILE, 4800827
CHILE, Antofagasta Antofagasta, CHILE, 1420000
CHILE, Reg Metropolitana de Santiago Santaigo, Reg Metropolitana de Santiago, CHILE, 8241470
CHILE, Reg Metropolitana de Santiago Santiago, Reg Metropolitana de Santiago, CHILE, 8420383
CHILE, Reg Metropolitana de Santiago Santiago, Reg Metropolitana de Santiago, CHILE, 7500921
CHILE, Reg Metropolitana de Santiago Santiago, Reg Metropolitana de Santiago, CHILE
FRANCE Bobigny, FRANCE, 93009
FRANCE Dijon, FRANCE, 21079
FRANCE LILLE, FRANCE, 59037
FRANCE Nantes, FRANCE, 44093
FRANCE PIERRE BENITE, FRANCE, 69495
GERMANY Berlin, GERMANY, 10117
GERMANY Hamburg, GERMANY, 20246
GERMANY Mannheim, GERMANY, 68167
GERMANY Minden, GERMANY, 32429
GERMANY München, GERMANY, 80337
ITALY, Napoli Napoli, ITALY, 80131
ITALY, Perugia Perugia, ITALY, 06126
SPAIN, Barcelona [Barcelona] Barcelona, Barcelona [Barcelona], SPAIN, 08035
SPAIN, Barcelona [Barcelona] Barcelona, Barcelona [Barcelona], SPAIN, 08036
SPAIN, Barcelona [Barcelona] Hospitalet de Llobregat, Barcelona [Barcelona], SPAIN, 08908
SPAIN, Cantabria Santander, Cantabria, SPAIN, 39008
UNITED STATES, California Beverly Hills, California, UNITED STATES, 90211